Universe Pharmaceuticals (UPC) Receivables - Other (2021 - 2025)

Universe Pharmaceuticals' Receivables - Other history spans 5 years, with the latest figure at $2.3 billion for Q3 2025.

  • On a quarterly basis, Receivables - Other fell 59.75% to $2.3 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 billion, a 59.75% decrease, with the full-year FY2025 number at $2.3 billion, down 59.75% from a year prior.
  • Receivables - Other hit $2.3 billion in Q3 2025 for Universe Pharmaceuticals, down from $5.7 billion in the prior quarter.
  • Over the last five years, Receivables - Other for UPC hit a ceiling of $5.7 billion in Q3 2024 and a floor of $236982.0 in Q3 2021.
  • Historically, Receivables - Other has averaged $1.6 billion across 5 years, with a median of $1.9 million in 2023.
  • Biggest five-year swings in Receivables - Other: surged 294996.63% in 2024 and later tumbled 59.75% in 2025.
  • Tracing UPC's Receivables - Other over 5 years: stood at $236982.0 in 2021, then surged by 50.34% to $356290.0 in 2022, then soared by 438.96% to $1.9 million in 2023, then surged by 294996.63% to $5.7 billion in 2024, then tumbled by 59.75% to $2.3 billion in 2025.
  • Business Quant data shows Receivables - Other for UPC at $2.3 billion in Q3 2025, $5.7 billion in Q3 2024, and $1.9 million in Q3 2023.